MRK - Merck & Co., Inc.
| Previous close | 85.06 |
| Open | 85.59 |
| Bid | 86.27 x 900 |
| Ask | 86.28 x 1100 |
| Day's range | 85.46 - 86.47 |
| 52-week range | 66.10 - 87.07 |
| Volume | 3,602,233 |
| Avg. volume | 10,248,552 |
| Market cap | 220.896B |
| Beta (3Y monthly) | 0.32 |
| PE ratio (TTM) | 24.19 |
| EPS (TTM) | 3.57 |
| Earnings date | 29 Oct 2019 |
| Forward dividend & yield | 2.20 (2.59%) |
| Ex-dividend date | 2019-09-13 |
| 1y target est | 94.93 |
- Zacks
Buy 5 Dow Stocks That Have Surged Despite Market Gyrations
Some members of the Dow 30 Index have offered impressive returns in the past three months and still have upside left.
- Zacks
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.
- Zacks
AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
- Zacks
Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.
- Zacks
Moleculin Completes Enrollment in Early-Stage Cancer Study
Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.
- Zacks
Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
- Business Wire
LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA, When Added to Standard-of-Care Bevacizumab, Significantly Reduced the Risk of Disease Progression or Death in Women Who Responded to Platinum-Base
- Zacks
Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
- Simply Wall St.
An Intrinsic Calculation For Merck & Co., Inc. (NYSE:MRK) Suggests It's 22% Undervalued
Does the August share price for Merck & Co., Inc. (NYSE:MRK) reflect what it's really worth? Today, we will estimate...
- Zacks
J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients
FDA approves J&J's (JNJ) pulmonary multidrug-resistant tuberculosis tablet Sirturo (bedaquiline) for the treatment of adolescent patients.
- Zacks
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2
Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the second quarter of 2019.
- Zacks
Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2019.
- Zacks
Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
Esperion Therapeutics (ESPR) reports mixed second-quarter results.
- Reuters - UK Focus
LIVE MARKETS-On our radar at the open
- Reuters - UK Focus
Merck KGaA's Q2 profit bolstered by drug milestone payments
- Business Wire
Merck Announces Leadership Changes to Investor Relations Team
Merck (MRK), known as MSD outside the United States and Canada, today announced that Peter Dannenbaum has been promoted to vice president, Investor Relations, effective Aug. 19, 2019. Teri Loxam, senior vice president, Investor Relations and Global Communications, will be leaving Merck to become chief financial officer of SQZ Biotech. “Merck has benefited from Teri’s leadership and skilled and principled approach to communicating with its many constituencies including those in the financial community.
- Zacks
Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.
- Business Wire
LYNPARZA® (olaparib) Phase 3 PROfound Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint
AstraZeneca and Merck’s LYNPARZA Improved Radiographic Progression Free Survival vs. Standard of Care in Patients Selected for BRCA 1/2 or ATM Mutations
- Reuters - UK Focus
UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute
British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo. While Ebola is a deadly and contagious disease, it is also still relatively rare, making the potential market for a vaccine sporadic and very likely unprofitable. GSK's vaccine candidates - two designed to protect against Ebola and one against the Marburg virus - will be transferred to the Sabin Vaccine Institute in Washington, D.C., the British drugmaker said in a statement.
- Zacks
Top Stock Reports: Mastercard, Verizon, Coca-Cola & More
Top Stock Reports: Mastercard, Verizon, Coca-Cola & More
- Zacks
Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates
Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.
- Motley Fool
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.
- Zacks
Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger
AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.
- Zacks
Has Merck & Co. (MRK) Outpaced Other Medical Stocks This Year?
Is (MRK) Outperforming Other Medical Stocks This Year?
- Investing.com
Stocks - Stocks Dive as Fed's Powell Sinks Future Easing Hopes
Investing.com – Stocks slumped Wednesday after the Federal Reserve cut its key interest rate to support the domestic economy amid slowing global growth, but Fed Chairman Jerome Powell indicated this was not the first cut of a monetary easing cycle.
